Recombinant Rat Cytochrome b-c1 complex subunit Rieske, mitochondrial (Uqcrfs1)

What is Cytochrome b-c1 complex subunit Rieske (Uqcrfs1) and what is its function in mitochondrial metabolism?

Cytochrome b-c1 complex subunit Rieske (Uqcrfs1) is a key component of the ubiquinol-cytochrome c reductase complex (Complex III) in the mitochondrial respiratory chain. This protein contains an iron-sulfur cluster that plays a critical role in electron transfer from ubiquinol to cytochrome c during oxidative phosphorylation. The Rieske protein participates in a process called the Q cycle, where protons are translocated across the mitochondrial inner membrane, contributing to the electrochemical gradient that drives ATP synthesis. This iron-sulfur cluster-containing protein serves as an essential electron carrier, facilitating the transfer of electrons within Complex III while maintaining the proton-motive force necessary for energy production .

What is the molecular structure of rat Uqcrfs1 and how does it compare to human and mouse orthologs?

Rat Uqcrfs1 is a protein with a calculated molecular weight of approximately 30 kDa, though it is often observed at around 25 kDa in experimental conditions such as Western blotting . The mature form of rat Uqcrfs1 consists of amino acids 79-274 of the full protein sequence, as the N-terminal portion serves as a mitochondrial targeting sequence that is cleaved during processing. The amino acid sequence of the mature protein is: SHTDIKVPDFSDYRRAEVLDSTKSSKESSEARKGFSYLVTATTTVGVAYAAKNAVSQFVSSMSASADVLAMSKIEIKLSDIPEGKNMAFKWRGKPLFVRHRTKKEIDQEAAVEVSQLRDPQHDLERVKKPEWVILIGVCTHLGCVPIANAGDFGGYYCPCHGSHYDASGRIRKGPAPLNLEVPTYEFTSGDVVVVG .

Rat Uqcrfs1 shares high sequence homology with human and mouse orthologs, making it a valuable model for studying mitochondrial function across species. This conservation is particularly evident in the iron-sulfur cluster binding domain, which is essential for the protein's electron transfer function in Complex III.

How is recombinant rat Uqcrfs1 protein typically expressed and purified for research applications?

Recombinant rat Uqcrfs1 is typically expressed in E. coli expression systems with an N-terminal His-tag to facilitate purification . The expression construct contains the mature form of the protein (amino acids 79-274), excluding the mitochondrial targeting sequence. After bacterial expression, the protein is purified using affinity chromatography, typically with Ni-NTA resin that binds the His-tag.

The purification protocol generally involves:

• Cell lysis under native or denaturing conditions

• Affinity purification using His-tag binding columns

• Washing steps to remove non-specifically bound proteins

• Elution using imidazole or pH changes

• Buffer exchange and concentration

• Quality control via SDS-PAGE to verify purity (>90% purity is standard)

The final product is often lyophilized for long-term storage and stability, and should be reconstituted in deionized sterile water to a concentration of 0.1-1.0 mg/mL before use. Addition of 5-50% glycerol is recommended for aliquots intended for long-term storage at -20°C/-80°C to prevent freeze-thaw damage .

What are the optimal storage and handling conditions for recombinant rat Uqcrfs1 to maintain protein stability and activity?

The optimal storage and handling of recombinant rat Uqcrfs1 requires careful attention to temperature, buffer conditions, and freeze-thaw cycles to maintain protein stability and functional activity. Lyophilized Uqcrfs1 should be stored at -20°C/-80°C upon receipt. Before opening, vials should be briefly centrifuged to bring the contents to the bottom, and reconstitution should be performed using deionized sterile water to a concentration of 0.1-1.0 mg/mL .

For long-term storage, it is essential to add glycerol to a final concentration of 5-50% (with 50% being recommended by manufacturers) and aliquot the protein solution to minimize freeze-thaw cycles . Working aliquots can be stored at 4°C for up to one week, but repeated freezing and thawing should be strictly avoided as this can lead to protein denaturation and loss of activity . The buffer system most commonly used is Tris/PBS-based buffer with 6% trehalose at pH 8.0, which helps maintain protein stability .

Researchers should take extra precautions during experimental handling, including keeping the protein on ice when in use and minimizing exposure to oxidizing conditions that could affect the iron-sulfur cluster integrity.

How can researchers effectively validate the structural integrity and activity of recombinant Uqcrfs1 in experimental settings?

Validating the structural integrity and functional activity of recombinant Uqcrfs1 requires a multi-faceted approach:

• SDS-PAGE Analysis: Confirms the protein's molecular weight (observed at approximately 25 kDa) and purity (should be >90%) .

• Western Blot Validation: Using specific antibodies against Uqcrfs1 with recommended dilutions of 1:1000-1:8000 to verify protein identity and expression levels .

• Spectroscopic Analysis: UV-Vis spectroscopy can assess the iron-sulfur cluster integrity, with characteristic absorption peaks indicating proper folding of the iron-sulfur domain.

• Enzymatic Activity Assays: Measuring electron transfer rates from ubiquinol to cytochrome c when incorporated into membrane preparations or reconstituted systems.

• Structural Analysis: Circular dichroism (CD) spectroscopy to evaluate secondary structure composition and proper folding.

• Functional Incorporation: Complementation assays in Complex III-deficient systems to verify functional activity in a biological context.

• Redox Potential Measurements: Electrochemical techniques to assess the iron-sulfur cluster's ability to participate in electron transfer reactions.

A comprehensive validation should include multiple methods to ensure both structural integrity and functional competence before proceeding with more complex experimental applications.

What methodologies are available for studying protein-protein interactions involving Uqcrfs1 within the cytochrome b-c1 complex?

Several sophisticated methodologies can be employed to investigate protein-protein interactions involving Uqcrfs1 within the cytochrome b-c1 complex:

• Co-Immunoprecipitation (Co-IP): Using antibodies against Uqcrfs1 or other Complex III components to pull down interaction partners. The recommended antibody concentration for IP is 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate .

• Proximity Labeling Techniques: BioID or APEX2 fusion proteins can identify proteins in close proximity to Uqcrfs1 in its native environment.

• Crosslinking Mass Spectrometry (XL-MS): Covalent crosslinking followed by mass spectrometry analysis can map interaction interfaces between Uqcrfs1 and other Complex III subunits.

• Förster Resonance Energy Transfer (FRET): When coupled with fluorescently tagged proteins, FRET can reveal dynamic interactions and conformational changes in real-time.

• Blue Native PAGE: Preserves protein complexes in their native state, allowing for analysis of intact Complex III and subcomplexes containing Uqcrfs1.

• Cryo-Electron Microscopy: Provides structural insights into the positioning of Uqcrfs1 within the entire Complex III at near-atomic resolution.

• Yeast Two-Hybrid Assays: Modified for membrane proteins, this can screen for specific interaction domains between Uqcrfs1 and other proteins.

• Surface Plasmon Resonance (SPR): Quantitative measurement of binding affinities between purified Uqcrfs1 and potential interaction partners.

These methodologies can be strategically combined to build a comprehensive understanding of Uqcrfs1's interaction network and its functional implications within the respiratory chain.

How does post-translational modification affect Uqcrfs1 function, and what techniques are available to study these modifications?

• Proteolytic Processing: The N-terminal mitochondrial targeting sequence of Uqcrfs1 is cleaved upon import into mitochondria, producing the mature form (amino acids 79-274) . This processing, mediated in part by UQCRC1 and UQCRC2 subunits of Complex III, is essential for proper integration of Uqcrfs1 into the complex .

• Oxidative Modifications: Oxidation of key residues, particularly iron-sulfur cluster-coordinating cysteines, can impair electron transfer functionality. Studies have shown that oxidative stress can alter the conformational dynamics of Complex III subunits, including significant Root Mean Square Fluctuation (RMSF) changes in UQCRFS1 compared to non-oxidized controls .

Techniques to study these modifications include:

• Mass Spectrometry: LC-MS/MS with electron transfer dissociation (ETD) can identify specific PTM sites and their occupancy levels.

• Site-Directed Mutagenesis: Replacing potentially modified residues to assess functional consequences.

• Redox Proteomics: Specific labeling of oxidized residues combined with MS analysis.

• Molecular Dynamics Simulations: Computational approaches that can predict structural changes resulting from PTMs, as demonstrated in studies of oxidized CIII components .

• Activity Assays: Comparing electron transfer rates between native and modified forms of the protein.

Understanding these modifications is crucial as they represent potential regulatory mechanisms and targets for therapeutic intervention in mitochondrial disorders.

What insights have molecular dynamics simulations provided about Uqcrfs1 structure and function in Complex III?

Molecular dynamics (MD) simulations have provided valuable insights into the structural dynamics and functional mechanisms of Uqcrfs1 within Complex III:

• Conformational Flexibility: MD simulations have revealed that UQCRFS1 exhibits significant Root Mean Square Fluctuation (RMSF) in response to oxidative modifications of other Complex III components, suggesting an interconnected network of structural stability .

• Domain Movements: The iron-sulfur cluster domain of Uqcrfs1 undergoes a large-scale movement during the catalytic cycle, transitioning between positions proximal to cytochrome b and cytochrome c1. Simulations have helped characterize the energetics and kinetics of this domain movement.

• Interface Interactions: Simulations have mapped critical interaction networks between Uqcrfs1 and other subunits, particularly highlighting the importance of hydrophobic and electrostatic interactions at the interfaces with UQCRC1 and UQCRC2.

• Electron Transfer Pathways: Quantum mechanics/molecular mechanics (QM/MM) simulations have elucidated the electron transfer pathway from the iron-sulfur cluster to cytochrome c1, identifying key residues that facilitate this process.

• Response to Oxidative Damage: When oxidative damage occurs in Complex III (such as at W395 of UQCRC1), MD simulations show propagating structural alterations that affect the dynamics of UQCRFS1, potentially explaining decreased enzymatic activity observed in experimental studies .

These computational insights complement experimental approaches and provide atomic-level details of mechanistic processes that are challenging to observe experimentally, offering new hypotheses for targeted experimental validation.

How do mutations in Uqcrfs1 affect Complex III assembly and electron transport chain function?

Experimental models with Uqcrfs1 mutations have been valuable for understanding mitochondrial disease mechanisms, revealing that even subtle alterations in this protein can have cascading effects on cellular bioenergetics and redox homeostasis.

What role does Uqcrfs1 play in mitochondrial dysfunction associated with neurodegenerative diseases?

Uqcrfs1, as a critical component of Complex III, plays a significant role in mitochondrial dysfunction associated with neurodegenerative diseases through several interrelated mechanisms:

• Electron Transport Chain Integrity: Proper functioning of Uqcrfs1 is essential for maintaining electron flow through Complex III. Alterations in its expression or function can disrupt this process, leading to decreased ATP production particularly problematic in high-energy demanding neurons .

• ROS Generation and Oxidative Stress: Dysfunction of Uqcrfs1 can increase electron leakage from Complex III, resulting in elevated reactive oxygen species (ROS) production. This oxidative stress is a common feature in neurodegenerative conditions like Parkinson's and Alzheimer's disease .

• Nigral Dopaminergic Neuron Maintenance: Research suggests that proper mitochondrial function, including intact Uqcrfs1 activity, plays a particularly important role in maintaining the viability of nigral dopaminergic neurons, which are selectively vulnerable in Parkinson's disease .

• Protein Aggregation: Mitochondrial dysfunction resulting from altered Uqcrfs1 function can exacerbate protein misfolding and aggregation, hallmarks of many neurodegenerative diseases, through disrupted protein quality control mechanisms and increased oxidative damage to proteins.

• Neuroinflammation: Dysfunctional Complex III contributes to activation of inflammatory pathways through mitochondrial damage-associated molecular patterns (DAMPs) and altered immune cell metabolism.

Understanding how Uqcrfs1 dysfunction contributes to these pathological processes provides potential targets for therapeutic interventions aimed at preserving mitochondrial function in neurodegenerative diseases.

How can recombinant Uqcrfs1 be used to study mitochondrial complex assembly and function in vitro?

Recombinant Uqcrfs1 serves as a valuable tool for investigating mitochondrial complex assembly and function through various in vitro experimental approaches:

• Reconstitution Experiments: Purified recombinant Uqcrfs1 can be used to reconstitute Complex III activity in membrane systems or liposomes, allowing for controlled studies of electron transfer kinetics and proton translocation.

• Assembly Studies: The incorporation of tagged recombinant Uqcrfs1 into partially assembled Complex III can reveal the sequence and requirements for complex maturation, particularly the role of UQCRC1 and UQCRC2 in processing and integrating Uqcrfs1 .

• Structure-Function Analysis: Site-directed mutagenesis of recombinant Uqcrfs1 permits systematic investigation of how specific residues contribute to protein stability, complex assembly, and electron transfer function.

• Protein-Protein Interaction Mapping: His-tagged recombinant Uqcrfs1 can be used in pull-down assays to identify novel interaction partners or to characterize the strength and specificity of known interactions within Complex III.

• Antibody Validation: Recombinant Uqcrfs1 serves as a positive control for validating the specificity and sensitivity of antibodies used in research and diagnostic applications .

• Inhibitor Screening: In reconstituted systems, recombinant Uqcrfs1 enables high-throughput screening of compounds that modulate Complex III activity, potentially identifying novel therapeutic agents.

• Biophysical Characterization: Purified recombinant protein allows for detailed biophysical studies using techniques such as circular dichroism, isothermal titration calorimetry, and electron paramagnetic resonance to characterize the iron-sulfur cluster properties.

These applications collectively contribute to our understanding of both fundamental aspects of mitochondrial biology and the pathological mechanisms underlying mitochondrial diseases.

What novel therapeutic approaches target Uqcrfs1 and Complex III for mitochondrial disorders?

Emerging therapeutic approaches targeting Uqcrfs1 and Complex III for mitochondrial disorders include:

• Small Molecule Stabilizers: Development of compounds that bind to Uqcrfs1 and stabilize its conformation, particularly protecting the iron-sulfur cluster from oxidative damage during cellular stress conditions.

• Gene Therapy Approaches: Delivery of wild-type Uqcrfs1 using viral vectors to complement genetic deficiencies or mutations, with targeting sequences ensuring proper mitochondrial localization.

• Allotopic Expression: Engineering nuclear-encoded, mitochondrially-targeted Uqcrfs1 with optimized codons for improved expression and import efficiency in patients with mitochondrial DNA-related Complex III deficiencies.

• Chaperone-Mediated Folding Enhancement: Identification of small molecules that promote proper folding of mutant Uqcrfs1 proteins, similar to approaches used for other mitochondrial proteins.

• Metabolic Bypass Strategies: Development of alternative electron carriers that can bypass defective Complex III, redirecting electron flow to maintain mitochondrial membrane potential and ATP production.

• Mitochondrially-Targeted Antioxidants: Compounds specifically designed to accumulate in mitochondria and neutralize ROS produced as a consequence of Complex III dysfunction, protecting Uqcrfs1 and other components from oxidative damage .

• Activation of Mitochondrial Biogenesis: Upregulation of PGC-1α and other factors that increase mitochondrial content, potentially compensating for reduced per-mitochondrion Complex III activity.

These therapeutic strategies are still largely in preclinical development but represent promising avenues for addressing mitochondrial disorders where Complex III dysfunction plays a central role.

What are the common challenges in detecting and analyzing Uqcrfs1 in tissue samples and how can they be overcome?

Researchers face several challenges when detecting and analyzing Uqcrfs1 in tissue samples, along with evidence-based solutions:

• Antibody Specificity and Cross-Reactivity:

  • Challenge: Many commercial antibodies show cross-reactivity with other mitochondrial proteins.

  • Solution: Validate antibodies using positive controls (recombinant Uqcrfs1) and negative controls (knockdown samples). For rat samples, antibodies with confirmed reactivity in rat heart tissue have shown good specificity at dilutions of 1:1000-1:8000 for Western blot .

• Protein Degradation During Extraction:

  • Challenge: The iron-sulfur cluster makes Uqcrfs1 susceptible to degradation during tissue processing.

  • Solution: Process tissues rapidly on ice, use fresh protease inhibitor cocktails, and include reducing agents like DTT or β-mercaptoethanol to preserve protein integrity.

• Subcellular Fractionation Efficiency:

  • Challenge: Incomplete mitochondrial isolation can dilute Uqcrfs1 signal.

  • Solution: Verify fractionation quality using markers for different cellular compartments; optimize centrifugation speeds and buffer compositions for the specific tissue type.

• Post-Translational Modifications Detection:

  • Challenge: Important PTMs can be lost during processing or difficult to detect.

  • Solution: Use phosphatase inhibitors during extraction; employ specialized techniques like Phos-tag gels for phosphorylation or specific redox proteomics approaches for oxidative modifications .

• Quantification Accuracy:

  • Challenge: Variable extraction efficiency can confound quantitative comparisons between samples.

  • Solution: Normalize to multiple mitochondrial markers (not just single housekeeping proteins); consider using spike-in standards of recombinant Uqcrfs1 for absolute quantification .

• Tissue-Specific Expression Levels:

  • Challenge: Uqcrfs1 expression varies across tissues, making detection difficult in low-expression samples.

  • Solution: Adjust protein loading amounts based on tissue type; for IHC applications, optimize antigen retrieval methods (TE buffer pH 9.0 has shown good results) .

By implementing these methodological refinements, researchers can achieve more reliable and reproducible analyses of Uqcrfs1 in diverse tissue samples.

How should researchers design experiments to investigate the specific role of Uqcrfs1 in oxidative phosphorylation?

Designing rigorous experiments to investigate Uqcrfs1's specific role in oxidative phosphorylation requires a multi-faceted approach:

• Loss-of-Function Models:

  • RNA Interference: Use siRNA or shRNA targeting Uqcrfs1 with carefully designed controls (scrambled sequences) to achieve partial knockdown.

  • CRISPR/Cas9 Gene Editing: For complete knockout studies in cell lines, though complete absence may be lethal due to the essential nature of Uqcrfs1.

  • Conditional Knockouts: Tissue-specific or inducible Uqcrfs1 deletion in animal models to avoid developmental lethality.

• Rescue Experiments:

  • Re-express wild-type or mutant Uqcrfs1 in knockdown/knockout backgrounds to establish causality and structure-function relationships.

  • Use the full amino acid sequence of mature rat Uqcrfs1 (aa 79-274) for accurate physiological relevance .

• Functional Assays:

  • Oxygen Consumption Measurements: High-resolution respirometry to assess different respiratory states (basal, maximal, spare capacity).

  • Complex III Activity: Spectrophotometric assays measuring cytochrome c reduction rates.

  • Proton Pumping: Fluorescence-based assays to measure proton translocation across membranes.

  • ATP Production: Luminescence-based assays to directly measure oxidative phosphorylation output.

• Structural Integration Analysis:

  • Blue Native PAGE to assess Complex III assembly and supercomplex formation.

  • Immunoprecipitation with recommended antibody concentrations (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate) to study interaction partners.

• Mitochondrial Morphology and Distribution:

  • Confocal microscopy with mitochondrial markers to assess potential secondary effects on mitochondrial dynamics.

• Controls and Validation:

  • Include both positive controls (known Complex III inhibitors like antimycin A) and negative controls.

  • Validate phenotypes with multiple independent methods and across different cell types/tissues.

  • Consider compensatory mechanisms that may mask acute effects in chronic models.

This comprehensive experimental design will allow researchers to dissect both the direct role of Uqcrfs1 in electron transport and its broader impacts on mitochondrial function and cellular metabolism.

What are the critical considerations for comparing experimental results across different model systems when studying Uqcrfs1?

When comparing experimental results across different model systems in Uqcrfs1 research, researchers must consider several critical factors to ensure valid interpretations:

By carefully addressing these considerations, researchers can more accurately translate findings across experimental systems and improve the reproducibility and clinical relevance of Uqcrfs1 research.

What are the most promising future directions for Uqcrfs1 research in mitochondrial biology?

The future of Uqcrfs1 research in mitochondrial biology holds several promising directions that could significantly advance our understanding of mitochondrial function and disease mechanisms:

• High-Resolution Structural Studies: Advances in cryo-electron microscopy may allow visualization of conformational changes in Uqcrfs1 during the catalytic cycle of Complex III, providing unprecedented insights into electron transfer mechanisms and potential targets for therapeutic intervention.

• Tissue-Specific Functions: Investigating the role of Uqcrfs1 in different tissues, particularly in neurons that are highly dependent on oxidative phosphorylation, could reveal specialized functions or vulnerabilities relevant to neurodegenerative diseases .

• Post-Translational Regulation: Comprehensive characterization of Uqcrfs1 post-translational modifications and how they change under physiological and pathological conditions will likely uncover new regulatory mechanisms of mitochondrial respiration.

• Supercomplexes Dynamics: Exploring how Uqcrfs1 contributes to the formation and stability of respiratory supercomplexes could reveal higher-order organizational principles governing mitochondrial electron transport efficiency.

• Therapeutic Development: Building on our understanding of Uqcrfs1 structure and function, development of small molecules that can stabilize or enhance Complex III activity represents a promising approach for treating mitochondrial disorders.

• Systems Biology Approaches: Integration of Uqcrfs1 research with broader mitochondrial and cellular networks using multi-omics approaches will place this protein in its proper context within cellular metabolism and signaling pathways.

• Aging and Senescence: Investigating how Uqcrfs1 function changes during aging and cellular senescence may provide insights into fundamental mechanisms of age-related decline in mitochondrial function.